Evidence map›Paper›PMID 33235741›Full record

ArticleClinical case reports2020

Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1.

Ken-Ichi Yasuda, Yoshimasa Nobeyama, Takaoki Ishiji, Arihito Ota, Akihiko Asahina

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. [Treatment and progress of cutaneous neurofibroma].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ken-Ichi YasudaDepartment of Dermatology The Jikei University School of Medicine Tokyo Japan.
Yoshimasa NobeyamaDepartment of Dermatology The Jikei University School of Medicine Tokyo Japan.ORCID https://orcid.org/0000-0002-0125-8930
Takaoki IshijiDepartment of Dermatology The Jikei University School of Medicine Tokyo Japan.
Arihito OtaDepartment of Dermatology The Jikei University School of Medicine Tokyo Japan.
Akihiko AsahinaDepartment of Dermatology The Jikei University School of Medicine Tokyo Japan.
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c-NFs) and promote growth of pre-existing c-NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.

Indexed as

cutaneous neurofibromaimatinib mesylateneurofibromatosis type 1NF1paradoxical reactionRASopathy

Identifiers

PMID33235741
PMCPMC7669387
OpenAlexW3037299228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.